NO322176B1 - Anvendelse av pox inducere omfattende en kombinasjon av henholdsvis flere pox virus og parapox virus for fremstilling av medikamentet for prefinal tumorterapi for a lindre smerte og optimalisere velbefinnende til pasienter. - Google Patents
Anvendelse av pox inducere omfattende en kombinasjon av henholdsvis flere pox virus og parapox virus for fremstilling av medikamentet for prefinal tumorterapi for a lindre smerte og optimalisere velbefinnende til pasienter. Download PDFInfo
- Publication number
- NO322176B1 NO322176B1 NO19984782A NO984782A NO322176B1 NO 322176 B1 NO322176 B1 NO 322176B1 NO 19984782 A NO19984782 A NO 19984782A NO 984782 A NO984782 A NO 984782A NO 322176 B1 NO322176 B1 NO 322176B1
- Authority
- NO
- Norway
- Prior art keywords
- patients
- inducers
- treatment
- pox
- virus
- Prior art date
Links
- 239000000411 inducer Substances 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 241000700639 Parapoxvirus Species 0.000 title claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 title claims description 17
- 238000002560 therapeutic procedure Methods 0.000 title claims description 15
- 241000700605 Viruses Species 0.000 title claims description 11
- 208000002193 Pain Diseases 0.000 title claims description 10
- 230000036407 pain Effects 0.000 title claims description 10
- 229940079593 drug Drugs 0.000 title claims description 9
- 230000036642 wellbeing Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 abstract description 4
- 241000282414 Homo sapiens Species 0.000 abstract description 3
- 230000002163 immunogen Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 48
- 241000700647 Variola virus Species 0.000 description 30
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 28
- 229910052802 copper Inorganic materials 0.000 description 28
- 239000010949 copper Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 230000007815 allergy Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000002036 metaphylactic effect Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000037164 Collema parvum Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 241000200696 Halictus simplex Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 101000921780 Solanum tuberosum Cysteine synthase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229960004250 polygeline Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Control Of El Displays (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19614810 | 1996-04-15 | ||
| PCT/DE1997/000761 WO1997038724A1 (de) | 1996-04-15 | 1997-04-14 | Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO984782D0 NO984782D0 (no) | 1998-10-14 |
| NO984782L NO984782L (no) | 1998-12-15 |
| NO322176B1 true NO322176B1 (no) | 2006-08-21 |
Family
ID=7791302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19984782A NO322176B1 (no) | 1996-04-15 | 1998-10-14 | Anvendelse av pox inducere omfattende en kombinasjon av henholdsvis flere pox virus og parapox virus for fremstilling av medikamentet for prefinal tumorterapi for a lindre smerte og optimalisere velbefinnende til pasienter. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6162600A (da) |
| EP (1) | EP0885013B1 (da) |
| JP (1) | JP3568208B2 (da) |
| KR (1) | KR100302994B1 (da) |
| CN (1) | CN1165343C (da) |
| AT (1) | ATE203678T1 (da) |
| AU (1) | AU706729B2 (da) |
| BR (1) | BR9708679A (da) |
| CA (1) | CA2251690C (da) |
| DE (2) | DE59704194D1 (da) |
| DK (1) | DK0885013T3 (da) |
| ES (1) | ES2125846T3 (da) |
| GR (1) | GR3037049T3 (da) |
| HU (1) | HU224308B1 (da) |
| NO (1) | NO322176B1 (da) |
| NZ (1) | NZ332243A (da) |
| PL (1) | PL329353A1 (da) |
| PT (1) | PT885013E (da) |
| SI (1) | SI0885013T1 (da) |
| WO (1) | WO1997038724A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10122233A1 (de) * | 2000-07-11 | 2002-01-24 | Bayer Ag | Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen |
| UY26832A1 (es) * | 2000-07-11 | 2002-01-31 | Bayer Ag | Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer |
| AR028800A1 (es) * | 2000-07-11 | 2003-05-21 | Bayer Ag | Uso de cepas de parapoxvirus ovis contra fibrosis de organos |
| AU2002353031A1 (en) | 2001-12-07 | 2003-06-23 | Bayer Corporation | Use of parapox b2l protein to treat cancer and modify immune responses |
| CN1984666A (zh) * | 2004-07-13 | 2007-06-20 | 爱库里斯股份有限两合公司 | 与其他抗病毒剂联合治疗hiv/aids的副痘病毒 |
| DE102004045758A1 (de) * | 2004-09-21 | 2006-04-06 | Toximed Gmbh | Pharmazeutischer Wirkstoff gegen das HIV-Syndrom |
| DE102005027956B4 (de) * | 2005-06-16 | 2009-10-22 | Mayr, Anton, Prof. Dr. Dr. h.c. mult. | Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3504940C2 (de) * | 1984-02-17 | 1997-11-06 | Bayer Ag | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel |
| US6290962B1 (en) * | 1992-11-03 | 2001-09-18 | Oravax, Inc. | Urease-based vaccine and treatment for helicobacter infection |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
1997
- 1997-04-14 PT PT97922838T patent/PT885013E/pt unknown
- 1997-04-14 EP EP97922838A patent/EP0885013B1/de not_active Expired - Lifetime
- 1997-04-14 AU AU28858/97A patent/AU706729B2/en not_active Ceased
- 1997-04-14 DE DE59704194T patent/DE59704194D1/de not_active Expired - Fee Related
- 1997-04-14 PL PL97329353A patent/PL329353A1/xx unknown
- 1997-04-14 DE DE19780300T patent/DE19780300D2/de not_active Expired - Lifetime
- 1997-04-14 CN CNB971938202A patent/CN1165343C/zh not_active Expired - Fee Related
- 1997-04-14 JP JP53664997A patent/JP3568208B2/ja not_active Expired - Lifetime
- 1997-04-14 NZ NZ332243A patent/NZ332243A/xx unknown
- 1997-04-14 KR KR1019980708260A patent/KR100302994B1/ko not_active Expired - Fee Related
- 1997-04-14 DK DK97922838T patent/DK0885013T3/da active
- 1997-04-14 HU HU9901299A patent/HU224308B1/hu not_active IP Right Cessation
- 1997-04-14 WO PCT/DE1997/000761 patent/WO1997038724A1/de not_active Ceased
- 1997-04-14 SI SI9730186T patent/SI0885013T1/xx unknown
- 1997-04-14 BR BR9708679-7A patent/BR9708679A/pt not_active Application Discontinuation
- 1997-04-14 ES ES97922838T patent/ES2125846T3/es not_active Expired - Lifetime
- 1997-04-14 CA CA002251690A patent/CA2251690C/en not_active Expired - Fee Related
- 1997-04-14 AT AT97922838T patent/ATE203678T1/de not_active IP Right Cessation
-
1998
- 1998-10-14 US US09/171,269 patent/US6162600A/en not_active Expired - Fee Related
- 1998-10-14 NO NO19984782A patent/NO322176B1/no unknown
-
2001
- 2001-10-30 GR GR20010401921T patent/GR3037049T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1165343C (zh) | 2004-09-08 |
| DK0885013T3 (da) | 2001-11-05 |
| SI0885013T1 (da) | 2001-12-31 |
| PL329353A1 (en) | 1999-03-29 |
| JP2000501114A (ja) | 2000-02-02 |
| BR9708679A (pt) | 2000-01-04 |
| HUP9901299A2 (hu) | 1999-07-28 |
| AU2885897A (en) | 1997-11-07 |
| HU224308B1 (hu) | 2005-07-28 |
| ES2125846T3 (es) | 2001-12-16 |
| KR100302994B1 (ko) | 2001-11-30 |
| DE19780300D2 (de) | 1999-06-17 |
| GR3037049T3 (en) | 2002-01-31 |
| WO1997038724A1 (de) | 1997-10-23 |
| NZ332243A (en) | 2000-10-27 |
| HUP9901299A3 (en) | 2000-03-28 |
| PT885013E (pt) | 2002-01-30 |
| CA2251690C (en) | 2005-11-08 |
| US6162600A (en) | 2000-12-19 |
| NO984782L (no) | 1998-12-15 |
| EP0885013B1 (de) | 2001-08-01 |
| CA2251690A1 (en) | 1997-10-23 |
| AU706729B2 (en) | 1999-06-24 |
| JP3568208B2 (ja) | 2004-09-22 |
| KR20000005479A (ko) | 2000-01-25 |
| DE59704194D1 (de) | 2001-09-06 |
| ATE203678T1 (de) | 2001-08-15 |
| CN1215996A (zh) | 1999-05-05 |
| EP0885013A1 (de) | 1998-12-23 |
| NO984782D0 (no) | 1998-10-14 |
| ES2125846T1 (es) | 1999-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9561263B2 (en) | Treatment of inflammatory illnesses with ACE2 | |
| van der Spuy, S., Levy, DW & Levin | Cimetidine in the treatment of herpesvirus infections | |
| NO322176B1 (no) | Anvendelse av pox inducere omfattende en kombinasjon av henholdsvis flere pox virus og parapox virus for fremstilling av medikamentet for prefinal tumorterapi for a lindre smerte og optimalisere velbefinnende til pasienter. | |
| JP2000506539A (ja) | 治療目的のヒスタミン投与 | |
| US10413586B2 (en) | Antiviral agent comprising recombinant mistletoe lectins | |
| CN1845756A (zh) | 用于治疗疱疹感染的方法和组合物 | |
| US9636364B2 (en) | Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve | |
| US20180117126A1 (en) | Treatment of inflammatory illnesses with ace2 | |
| JPWO2016195086A1 (ja) | アレルギー性疾患の治療薬 | |
| Emery et al. | Immune-based therapies in HIV infection: recent developments | |
| CN106539815B (zh) | 环二核苷酸在防治多发性硬化症中的应用 | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| CN108014337B (zh) | 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物 | |
| Wolf et al. | Syngeneic HSCT in Combination with Post-Transplant Cyclophosphamide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) | |
| RU2195314C1 (ru) | Способ лечения больных с атопическим дерматитом | |
| CA2388933C (en) | Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases | |
| RU2189811C2 (ru) | Способ профилактики и лечения респираторных болезней телят | |
| WO2022002060A1 (en) | Method for antiviral and cytokine storm treatment | |
| CN108014336B (zh) | 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物 | |
| TWI527589B (zh) | Ｎｒｆ－１蛋白質之用途 | |
| RU2173171C1 (ru) | Способ лечения больных клещевым энцефалитом | |
| CN103169966A (zh) | 一种治疗系统性红斑狼疮的药物组合物 | |
| Thomas | Interferon options | |
| JPH11279077A (ja) | 筋炎予防治療剤 | |
| AU2006293690A1 (en) | Modifying leukocyte function |